Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914197 | 0.87 | USP2 (0.40) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL571404 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL18696436 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL1086226 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL20826636 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL23150890 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL31191651 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL2286177 | 0.82 | USP2 (0.44) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL16340420 | 0.82 | NR1H2 (0.46) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL21590786 | 0.82 | USP2 (0.39) | USP2SMN1; SMN2NR1H2HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634194-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024222894-A1 | BENZOFURAN COMPOUNDS AND THEIR USE AS PI3K ALPHA INHIBITORS | LAEKNA PHARMACEUTICAL NINGBO CO., LTD. (CN) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024130068-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-110278711-B | Tricyclosulfones as rory modulators | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| CN-106188175-B | Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds | 轩竹(北京)医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132760-A1 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| CN-101868472-A | Antibacterial aminoglycoside analogs | ACHAOGEN INC | 2010-10-20 | — | — | CN | disclosed |
| EP-2217610-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | USP2 3805/4885SMN1; SMN2 2895/4885NR1H2 1577/4885 |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | USP2 3805/4885SMN1; SMN2 2895/4885NR1H2 1577/4885 |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | USP2 4648/4885SMN1; SMN2 2004/4885NR1H2 1918/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | USP2 3805/4885SMN1; SMN2 2895/4885NR1H2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.